

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:)	Group Art Unit: 1644
GELFAND et al.)	Examiner: Huynh, Phuong N.
Serial No.: 09/809,753)	Confirmation No.: 5001
Filed: March 14, 2001)	
Atty. File No.: 2879-74)	<u>SHOWING OF PRIORITY</u>
For: "METHOD FOR REDUCING)	<u>UNDER 37 CFR 41.202(d)(1)</u>
ALLERGEN-INDUCED AIRWAY)	
HYPERRESPONSIVENESS")	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

Dear Sir:

We, Erwin W. Gelfand and Azzeddine Dakhama, each declare as follows:

1. I am a co-inventor of the above-referenced patent application and am familiar with the application.
2. This Showing of Priority Under 37 CFR 41.202(d)(1) is being submitted in conjunction with a Response to a final Office Action mailed on May 5, 2006 and a Request for Continued Examination, filed on this same date.
3. The above-referenced patent application has an earliest constructive reduction to practice that is later than the apparent earliest constructive reduction to practice for U.S. Patent No. 6,743,429 by Cadieux, issued on June 1, 2004, filed in the United States on December 30, 1999, and having an earliest priority date of December 24, 1999.
4. This Showing establishes that the Applicant of the above-referenced patent application would prevail on priority if an interference is declared and the opponent does not oppose the showing. Specifically, this Showing provides factual evidence that the invention as claimed in the above-identified patent application was actually reduced to practice prior to the earliest priority date of December 24, 1999 of U.S. Patent No. 6,743,429 and establishes a date of actual reduction to practice of at least March 2, 1999. All acts relied upon to establish the dates of actual reduction to practice were carried out in the United States.

Evidence of Actual Reduction To Practice

The invention presently claimed in the above-identified patent application was actually reduced to practice on at least March 2, 1999, which is several months prior to the earliest apparent date of constructive reduction to practice of U.S. Patent No. 6,743,429.

As evidence of actual reduction to practice by at least March 2, 1999, enclosed as Exhibit A is a notebook page from an experiment that was completed by the inventors on March 2, 1999. Also enclosed is a data table and figure from an additional experiment that was completed by the inventors by at least July 23, 1999. Each of these experiments demonstrate that administration of calcitonin gene related peptide (CGRP) to a mammal inhibits allergen-induced airway hyperresponsiveness (AHR) in the mammal.

Specifically, in the experiment completed on March 2, 1999, referring to Exhibit A, mice were sensitized by intraperitoneal injection of an allergen (*i.e.*, ovalbumin) and were then exposed by inhalation to a nebulized amount of the allergen (ovalbumin) that is sufficient to induce airway hyperresponsiveness (AHR) in the mice in the absence of treatment with CGRP (see the designation of "OVA ipNeb" on page A). Control mice received nebulized allergen (ovalbumin) only (see the designation of "OVA Neb" on page A). One group of mice receiving the intraperitoneal ovalbumin sensitization and nebulized ovalbumin challenge was treated by intraperitoneal administration of CGRP before the challenge (see the designation of "OVA ipNeb/CGRP ip x3" on page A). Airway function was assessed *in vivo* by measuring changes in lung resistance (R_L) in response to intratracheal challenge with aerosolized methacholine at doses of 1.56, 3.12, 6.25, 12.5 and 25 mg/ml in saline as indicated in Exhibit A. In addition, recovered BAL fluids were examined for cellular composition as shown in the table in Exhibit A. At the bottom of Exhibit A, the experimental results conclude that the treatment with CGRP had no effect on eosinophils in the BAL fluid and that the treatment inhibited allergen-induced AHR.

The table shown on page 1 of Exhibit B contains the results from a study similar to that described in Exhibit A, which was completed on July 23, 1999, and shows that CGRP has an inhibitory effect on ovalbumin-induced airway hyperresponsiveness, which is an art-accepted example of allergen-induced airway hyperresponsiveness. The data are tabulated as follows:

Column 1 shows the increasing doses in mg/ml of aerosolized methacholine (Mch) which was administered intratracheally to mice to measure airway hyperresponsiveness.

Columns 2 and 3 show the mean and standard error, respectively, of the changes in lung resistance in response to each dose of methacholine for ovalbumin-sensitized and challenged mice (OVA). The changes are presented as percent increases from baseline values recorded after intratracheal administration of aerosolized saline (no methacholine).

Columns 4 and 5 show the mean and standard error, respectively, of the changes in lung resistance in response to each dose of methacholine for ovalbumin-sensitized and challenged mice that were treated with CGRP (OVA+CG). The changes are presented as percent increases

from baseline values recorded after intratracheal administration of aerosolized saline (no methacholine).

Columns 6 and 7 show the mean and standard error, respectively, of the changes in lung resistance in response to each dose of methacholine for ovalbumin-sensitized and challenged mice that were treated first with a CGRP antagonist (CGRP8-37) followed by CGRP (OVA+Antagonist+CG). The changes are presented as percent increases from baseline values recorded after intratracheal administration of aerosolized saline (no methacholine).

Columns 8 and 9 show the mean and standard error, respectively, of the changes in lung resistance in response to each dose of methacholine for non-sensitized control mice (PBS). The changes are presented as percent increases from baseline values recorded after intratracheal administration of aerosolized saline (no methacholine).

The Figure shown on page 2 of Exhibit B was produced from the data described on page 1 of Exhibit B and illustrates the results of the study, that CGRP inhibits OVA-induced airway hyperresponsiveness to methacholine.

These experiments, which were completed on March 2, 1999 and July 23, 1999, respectively, which is several months prior to December 24, 1999, therefore demonstrate that the claimed method of the present invention operated for its intended purpose (i.e., administration of CGRP to a mammal inhibits airway hyperresponsiveness in the mammal).

This factual evidence is believed to be sufficient to establish an actual reduction to practice of the claimed invention and establish that Applicant would prevail on priority if an interference is declared and the opponent does not oppose the showing.

5. I hereby declare that all statements made herein of my own are true and that all statements made on information and belief are believed to be true; and further that the statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the subject application or any patent issuing therefrom.

6.4.07


Date

6-4-07

Date



Erwin W. Gelfand



Azzeddine Dakhama

EXHIBIT A

March 2/89

Try count on OVA / Boxes

Signa

to get ~ 15³ in vivo

mouse ~ 2 vol blood circulating

Give 20 μ l (1:200) from stock 10⁻⁵ M

OVA N^o 6

OVA ipN^o 6

OVA ipN^o 6 / count ip x 3 (before each change).

MRN response ~~25~~, 25, 12.5, 6.25, 3.125, 1.56 - SA

Box count	Total (10 ³)	2 MAR	EB	LN	NS
2 MAR 99/1	70	99	-	-	1
2	68	97	-	1	2
3	75	98	1	-	1
4	72	96	1	1	2
5	254	54	40	4	2
6	286	62	34	3	1
7	315	48	41	7	4
8	235	67	27	8	-
9	246	52	44	1	3
10	380	43	54	2	1
11	215	61	35	3	1
12	270	47	40	2	1

→ No effect on EB

→ Saccharin on AMR (Reliability)

EXHIBIT B

- 2 -

AHR/RL Data/23JL99 X±SEM									
Tue, Dec 23, 2003 4:50 PM									
	1	2	3	4	5	6	7	8	9
	Dose of MCh	OVA	SD1	OVA+CG	SD2	OVA+Ant+CG	SD3	PBS	SD
1	0	100	0	100	0	100	0	100	0
2	1.56	137	1.5	109	1.1	129	8	120	2
3	3.12	257	22	134	7	253	32	176	18
4	6.25	456	37	186	5	491	104	260	42
5	12.5	632	16	244	30	603	48	277	34

- 3 -

Effect of CGRP on OVA-induced AHR to MCh